Quotient Clinical expands its formulation development services with the acquisition of Co-Formulate

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited.

Quotient Clinical has brought innovation to the drug development process through its unique Translational Pharmaceutics platform, which challenges the conventional industry approach by integrating formulation development, real-time GMP manufacturing and clinical testing. The acquisition of Co-Formulate reinforces and extends Quotient’s existing pharmaceutical development capabilities across solid, semi-solid and liquid formulations. Co-Formulate is based adjacent to Quotient’s new GMP facility in Nottingham, UK, which will enable seamless integration of formulation development and GMP manufacturing services.

Mark Egerton, Chief Executive Officer of Quotient Clinical, commented: “We are delighted that Co-Formulate has become part of our business. The company brings a wealth of formulation development experience in areas that complement our existing capabilities. Its expertise in helping customers to manage product life cycles and develop a range of product formats, including age-appropriate paediatric and geriatric formulations, will help us to extend our customer base and service portfolio. These are important areas of our growth strategy over the coming years.”

Huw Jones and Nazim Kanji, Directors and founders of Co-Formulate, said: “We are excited to join forces with Quotient Clinical. The co-location of our formulation development laboratories with Quotient’s new GMP manufacturing facility will deliver a real advantage for our customers. We will now be in a position to deliver seamless programs consisting of formulation development, clinical trial manufacturing and clinical testing, all under the umbrella of a single organisation.”

Financial terms of the transaction were not disclosed. Quotient Clinical’s legal advisors on the acquisition were Browne Jacobson, and Dow Schofield Watts performed financial due diligence. The shareholders of Co-Formulate received legal advice from Shakespeare Martineau, and financial advice from Realise Capital Partners.

For further information, please contact:

Gordon Cameron
Chief Financial Officer
Quotient Clinical
Tel: +44 (0)115 931 5148

Robin Bodicoat
Marketing Director
Quotient Clinical
Tel: +44 (0)115 931 5102

About Quotient Clinical

Quotient Clinical offers unique services – based on its Translational Pharmaceutics® platform – that integrate formulation development, real-time drug product manufacturing and clinical testing, significantly reducing the time and cost of bringing a drug to market.
For more than 20 years, Quotient Clinical has brought innovation to drug product development programs for pharmaceutical and biotechnology customers worldwide. The company is based in purpose-built, fully integrated facilities in the UK, where formulation development, real-time GMP manufacturing and early clinical trials are performed in the same facility. It employs over 280 staff, offering a full range of support services, from study set-up right through to data analysis and reporting. Quotient Clinical was recently acquired by specialist healthcare investor GHO Capital who will support the future development of the company.

About Co-Formulate

Co-Formulate Limited is a contract product development company that provides a comprehensive range of formulation development, analytical and regulatory services to clients in the pharmaceutical, OTC consumer healthcare, personal care, nutritional supplements and veterinary industries. The company was established in 2007 and is located in state-of-the-art laboratories and processing facilities in MediCity, Nottingham, UK, with a team of experienced scientists who assist clients with developing a wide range of product formulations, undertaking analytical and stability testing and the provision of regulatory services